STIEVAA GEL 0.01% .01 %
TRETINOIN : .01 % · DIN 00587958 · STIEFEL CANADA ULC
Health Canada status: CANCELLED POST MARKET
What is STIEVAA GEL 0.01%?
STIEVAA GEL 0.01% .01 % contains TRETINOIN : .01 %. It is listed in the Health Canada Drug Product Database under DIN 00587958, held by STIEFEL CANADA ULC, supplied as GEL for TOPICAL administration. Health Canada currently lists it as cancelled post market, status dated 31-Aug-2007. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 00587958 |
|---|---|
| Brand name | STIEVAA GEL 0.01% |
| Generic / active ingredient | TRETINOIN : .01 % |
| Manufacturer | STIEFEL CANADA ULC |
| Strength | .01 % |
| Dosage form | GEL |
| Route of administration | TOPICAL |
| Schedule | Prescription |
| ATC code | D10AD01 TRETINOIN |
| AHFS class | 84:16.00 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 31-Aug-2007 |
| Original market date | 1983-12-31 00:00:00 |
What can be used instead?
Other Canadian products sharing ATC code D10AD01 TRETINOIN. 6 of 31 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| RETIN-A | 0.025 % | GEL | BAUSCH HEALTH, CANADA INC. | MARKETED | DIN 00443816 |
| RETIN-A | 0.05 % | CREAM | BAUSCH HEALTH, CANADA INC. | MARKETED | DIN 00443794 |
| RETIN-A MICRO | 0.04 % | GEL | BAUSCH HEALTH, CANADA INC. | MARKETED | DIN 02264633 |
| RETIN-A MICRO | 0.1 % | GEL | BAUSCH HEALTH, CANADA INC. | MARKETED | DIN 02243914 |
| VITAMIN A ACID | 0.025 % | GEL | BAUSCH HEALTH, CANADA INC. | MARKETED | DIN 01926470 |
| VITAMIN A ACID | 0.05 % | GEL | BAUSCH HEALTH, CANADA INC. | MARKETED | DIN 01926489 |
| ALTRENO | 0.05 % | LOTION | BAUSCH HEALTH, CANADA INC. | APPROVED | DIN 02510243 |
| REJUVA-A | 0.025 % | CREAM | GLAXOSMITHKLINE INC | CANCELLED POST MARKET | DIN 02192640 |
| RENOVA | 0.05 % | CREAM | VALEANT CANADA LP / VALEANT CANADA S.E.C. | CANCELLED POST MARKET | DIN 02052407 |
| RETIN-A | 0.01 % | GEL | BAUSCH HEALTH, CANADA INC. | DORMANT | DIN 00870013 |
Who else supplies TRETINOIN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. TRETINOIN appears in 1362 registered pack listings across 7 markets, published on 6 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.